Alendronate after denosumab discontinuation in women previously exposed to bisphosphonates was not effective in preventing the risk of spontaneous multiple vertebral fractures: two case reports.

Détails

ID Serval
serval:BIB_0954776AB6A8
Type
Article: article d'un périodique ou d'un magazine.
Sous-type
Etude de cas (case report): rapporte une observation et la commente brièvement.
Collection
Publications
Titre
Alendronate after denosumab discontinuation in women previously exposed to bisphosphonates was not effective in preventing the risk of spontaneous multiple vertebral fractures: two case reports.
Périodique
Osteoporosis international
Auteur(s)
Lamy O., Fernández-Fernández E., Monjo-Henry I., Stoll D., Aubry-Rozier B., Benavent-Núñez D., Aguado P., Gonzalez-Rodriguez E.
ISSN
1433-2965 (Electronic)
ISSN-L
0937-941X
Statut éditorial
Publié
Date de publication
05/2019
Peer-reviewed
Oui
Volume
30
Numéro
5
Pages
1111-1115
Langue
anglais
Notes
Publication types: Journal Article
Publication Status: ppublish
Résumé
At denosumab discontinuation, an antiresorptive agent is indicated to reduce the high bone turnover, the rapid bone loss, and the risk of spontaneous vertebral fractures. We report two cases of postmenopausal women, previously exposed to bisphosphonates, treated with alendronate at denosumab discontinuation. Alendronate was ineffective to avoid spontaneous clinical vertebral fractures. They presented three and nine spontaneous vertebral fractures 8 and 12 months after denosumab discontinuation, respectively. Ineffectiveness of alendronate was attributed to insufficient control of the rebound as assessed by B-crosslaps measures in the first case, and partially to the high risk of fractures in the later. In both situations, the increased fracture risk may have favoured these new fractures. It is urgent to define effective therapeutic strategies to avoid spontaneous vertebral fractures after denosumab discontinuation.
Pubmed
Web of science
Création de la notice
28/01/2019 9:11
Dernière modification de la notice
03/02/2020 15:12
Données d'usage